"Cancer"

Generally speaking, mild gastritis, i.e. superficial gastritis, does not increase the risk of gastric cancer, but if not adjusted in time, it may further develop into atrophic gastritis, which is a state of "precancerous lesion".

The US FDA has approved a new leukaemia drug, Olutasidenib, which has been shown to be effective and has a controlled safety profile, resulting in the complete disappearance of cancer cells in 35% of patients enrolled, with efficacy lasting up to 25.9 months.

Every year, 40000 women die of breast cancer in the United States alone. When cancers are discovered at an early stage, they can often be cured. Mammography is the best alternative diagnostic method, but this method also has shortcomings. It often results in false positive results, leading to unnecessary surgery.

A new clinical trial update shows that oxitinib (known as Teresa, or 9291) nearly doubled disease-free survival and halved post-operative recurrence rates in lung cancer patients carrying an early stage EGFR mutation!

Both laryngeal cancer and laryngitis are common diseases, but there are some differences between these two diseases. Therefore, it is necessary for us to learn more about the common knowledge of laryngeal cancer and laryngitis, which can help us to prevent and detect the diseases.

Preoperative oxaliplatin-fluoropyrimidine chemotherapy given to colon cancer patients did not increase the risk of perioperative complications in colon cancer patients and did reduce postoperative recurrence rates, according to the results of the international phase 3/4 FOxTROT trial.

UniversityClinic Hamburg-Eppendorf, UKE was founded on 17 May 1889 in Hamburg, Germany's second largest city, and is one of Europe's leading hospitals and the NO.1 medical centre of its size in Hamburg.

Data from a study of a cancer vaccine combined with a PD-1 immune checkpoint inhibitor has recently been released, and the treatment has increased the survival of patients with advanced colorectal cancer by more than three times, with some patients surviving for more than 22 months so far.

The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.

New therapy for lung cancer!